AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23060625 — intervention group
Group type: EXPERIMENTAL
Intervention: rhAPC via intrabronchial instillation
Number of subjects: 12
Study 23060625 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 12
Study 21198719 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin 15 mg/kg once per day (group I)
Number of subjects: 30
Study 21198719 — intervention group
Group type: COMPARATOR
Intervention: Amikacin 7.5 mg/kg twice per day (group II)
Number of subjects: 30
Study 17350868 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (fluticasone propionate 200 mcg/day by metered dose inhaler/spacer combination)
Number of subjects: 96
Study 17350868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 17350868 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (fluticasone propionate)
Number of subjects: 96
Study 16427167 — intervention group
Group type: EXPERIMENTAL
Intervention: Toronto Western Spasmodic Torticollis Rating Scale
Number of subjects: 19
Study 16427167 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrogoniometry
Number of subjects: 19
Study 16427167 — intervention group
Group type: EXPERIMENTAL
Intervention: Toronto severity score
Number of subjects: 19
Study 16427167 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral bending and rotation velocities
Number of subjects: 19
Study 14563543 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 382
Study 14563543 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 382
Study 10851830 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐4
Number of subjects: 42
Study 10851830 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐10
Number of subjects: 42
Study 10851830 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐2
Number of subjects: 42
Study 10851830 — intervention group
Group type: COMPARATOR
Intervention: TNF alpha
Number of subjects: 42
Study 9351742 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide inhalation (30 ppm)
Number of subjects: 15
Study 7713205 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training combined with cycle ergometer training
Number of subjects: 42
Study 7713205 — intervention group
Group type: COMPARATOR
Intervention: Cycle ergometer training alone
Number of subjects: 42
Study 7713205 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training regimens
Number of subjects: 42
Study 2455106 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 12
Study 2455106 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 12
Study 31498109 — intervention group
Group type: COMPARATOR
Intervention: efavirenz-based ART
Number of subjects: 74
Study 31498109 — intervention group
Group type: COMPARATOR
Intervention: ritonavir-boosted atazanavir-based ART
Number of subjects: 74
Study 31498109 — intervention group
Group type: COMPARATOR
Intervention: efavirenz or atazanavir
Number of subjects: 74
Study 29071968 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitalstim electroacupuncture (EA) combined with swallowing rehabilitation training
Number of subjects: 80
Study 29071968 — intervention group
Group type: COMPARATOR
Intervention: Regular medication and swallowing function rehabilitation training
Number of subjects: 80
Study 26645524 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger essence inhalation (2 drops on gauze, repeated every 30 min for 2 hours)
Number of subjects: 120
Study 26645524 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger essence inhalation
Number of subjects: 120
Study 26645524 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 120
Study 23516249 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof ReSTOR® SN60D3 MIOL and Corneal® ACPI 11 CTR (group 1)
Number of subjects: 60
Study 23516249 — intervention group
Group type: COMPARATOR
Intervention: AcrySof ReSTOR® SN60D3 MIOL without CTR (group 2)
Number of subjects: 60
Study 23516249 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 60
Study 23516249 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (with CTR)
Number of subjects: 60
Study 21517667 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH), tinzaparin
Number of subjects: 96
Study 21517667 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 96
Study 18284511 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% Clobetasol + 2.5% zinc sulphate cream
Number of subjects: 47
Study 18284511 — intervention group
Group type: COMPARATOR
Intervention: 0.05% Clobetasol alone cream
Number of subjects: 47
Study 16585455 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 522
Study 16585455 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 522
Study 12728112 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturopathic Herbal Extract Ear Drops (NHED) 5 drops 3 times daily
Number of subjects: 171
Study 12728112 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturopathic Herbal Extract Ear Drops (NHED) with topical anesthetic 5 drops 3 times daily
Number of subjects: 171
Study 12728112 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthetic 5 drops 3 times daily
Number of subjects: 171
Study 12728112 — intervention group
Group type: COMPARATOR
Intervention: Oral amoxicillin 80 mg/kg/d (maximum 500 mg/dose) divided into 3 doses with either NHED or topical anesthetic
Number of subjects: 171
Study 12940661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of recombinant tissue plasminogen activator (3 mg in 3 mL diluted into 250 mL of physiological saline solution, given every 12 hours)
Number of subjects: 27
Study 10553534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg/day for 3 months
Number of subjects: 103
Study 10553534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg/day for 6 months
Number of subjects: 103
Study 10553534 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cilostazol)
Number of subjects: 103
Study 8909673 — intervention group
Group type: EXPERIMENTAL
Intervention: Full disclosure
Number of subjects: 45
Study 8909673 — intervention group
Group type: COMPARATOR
Intervention: Standard disclosure (leaflet)
Number of subjects: 45
Study 8909673 — intervention group
Group type: COMPARATOR
Intervention: Minimal disclosure
Number of subjects: 45
Study 1905501 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol, 200 micrograms four times a day
Number of subjects: 253
Study 1905501 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate, 1 g four times a day
Number of subjects: 253
Study 1905501 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of Misoprostol vs Sucralfate
Number of subjects: 253
Study 6359843 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg daily)
Number of subjects: 22
Study 6359843 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (360 mg daily)
Number of subjects: 22
Study 6359843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 3536631 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic fetal monitoring (EFM)
Number of subjects: 969
Study 3536631 — intervention group
Group type: COMPARATOR
Intervention: AUS (stethoscope monitoring)
Number of subjects: 969
Study 3536631 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods (AUS and EFM)
Number of subjects: 969
Study 29298077 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin only (900 mg/day)
Number of subjects: 40
Study 29298077 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Medicine (OMM) only
Number of subjects: 40
Study 29298077 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin plus OMM
Number of subjects: 40
Study 29078965 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (standardized needle manipulation at LI10 and LI11 for 2 minutes)
Number of subjects: 96
Study 29078965 — intervention group
Group type: COMPARATOR
Intervention: Mock laser control (inactive laser at LI10 and LI11 for 2 minutes)
Number of subjects: 96
Study 26144850 — intervention group
Group type: EXPERIMENTAL
Intervention: ROM-6 (monthly rifampicin, ofloxacin, and minocycline for six months)
Number of subjects: 268
Study 26144850 — intervention group
Group type: COMPARATOR
Intervention: PB-MDT (standard World Health Organization paucibacillary multidrug therapy)
Number of subjects: 268
Study 26144850 — intervention group
Group type: COMPARATOR
Intervention: PB-MDT
Number of subjects: 268
Study 26144850 — intervention group
Group type: EXPERIMENTAL
Intervention: ROM-6
Number of subjects: 268
Study 23210452 — intervention group
Group type: EXPERIMENTAL
Intervention: ThermoCool Surround Flow® catheter (SFc)
Number of subjects: 106
Study 23210452 — intervention group
Group type: COMPARATOR
Intervention: ThermoCool® catheter (TCc)
Number of subjects: 106
Study 21695893 — intervention group
Group type: COMPARATOR
Intervention: Calcium 440 mg/d and VD 100 IU/d
Number of subjects: 60
Study 21695893 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium 440 mg/d, VD 100 IU/d and soy isoflavone 100 mg/d
Number of subjects: 60
Study 18649869 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin administration
Number of subjects: 127
Study 18649869 — intervention group
Group type: COMPARATOR
Intervention: Saline administration (Control)
Number of subjects: 127
Study 16433735 — intervention group
Group type: COMPARATOR
Intervention: sham‐AD
Number of subjects: 180
Study 16433735 — intervention group
Group type: EXPERIMENTAL
Intervention: verum‐AD (disulfiram/calcium carbimide)
Number of subjects: 180
Study 16433735 — intervention group
Group type: EXPERIMENTAL
Intervention: long‐term AD intake
Number of subjects: 180
Study 16433735 — intervention group
Group type: COMPARATOR
Intervention: AD intake between months 13 and 20
Number of subjects: 180
Study 16433735 — intervention group
Group type: EXPERIMENTAL
Intervention: detrimental lapses and malignant relapses
Number of subjects: 180
Study 15333424 — intervention group
Group type: EXPERIMENTAL
Intervention: sivelestat (ONO-5046) 0.2 mg/kg/h for 14 days
Number of subjects: 24
Study 15333424 — intervention group
Group type: EXPERIMENTAL
Intervention: sivelestat (ONO-5046)
Number of subjects: 24
Study 15333424 — intervention group
Group type: COMPARATOR
Intervention: conventional therapy
Number of subjects: 24
Study 11079239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ostracized participants
Number of subjects: 1486
Study 9287061 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP group)
Number of subjects: 12
Study 9287061 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocket reduction through osseous surgery and apically‐positioned flap (OS group)
Number of subjects: 12
Study 9287061 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Widman flap (MWF group)
Number of subjects: 12
Study 9287061 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Widman flap and topical application of saturated citric acid at pH 1 for 3 minutes (CA group)
Number of subjects: 12
Study 9287061 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected sites
Number of subjects: 12
Study 8332925 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation letter with an appointment
Number of subjects: 299
Study 8332925 — intervention group
Group type: COMPARATOR
Intervention: Opportunistic invitation by GP
Number of subjects: 299
Study 3446303 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-limited therapy carried out by trainees
Number of subjects: 0
Study 3446303 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 29354935 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point sticking therapy combined with western medicine
Number of subjects: 123
Study 29354935 — intervention group
Group type: COMPARATOR
Intervention: Western medicine only (control group)
Number of subjects: 123
Study 26969754 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 26969754 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus parecoxib
Number of subjects: 0
Study 26969754 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 26969754 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 0
Study 25394430 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol administration to kidney donors
Number of subjects: 60
Study 25394430 — intervention group
Group type: COMPARATOR
Intervention: Control group (mannitol negative)
Number of subjects: 60
Study 23697857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal diclofenac (IVD) - 500 μg/0.1 mL
Number of subjects: 15
Study 23697857 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal triamcinolone (IVT) - 2 mg
Number of subjects: 15
Study 23697857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal diclofenac (IVD)
Number of subjects: 15
Study 23697857 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal triamcinolone (IVT)
Number of subjects: 15
Study 20598971 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring strategy using the CareLink network with automatic alerts for lung fluid overload, atrial fibrillation, and device integrity issues.
Number of subjects: 1720
Study 20598971 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring strategy using the CareLink network.
Number of subjects: 1720
Study 20598971 — intervention group
Group type: COMPARATOR
Intervention: Standard in-office follow-up.
Number of subjects: 1720
Study 18795515 — intervention group
Group type: EXPERIMENTAL
Intervention: NovaMin dentifrice
Number of subjects: 71
Study 18795515 — intervention group
Group type: COMPARATOR
Intervention: SrCl2 dentifrice
Number of subjects: 71
Study 18795515 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 71
Study 17042147 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine hydrochloride (5 mg)‐pseudoephedrine hydrochloride (120 mg) (cetirizine‐D) twice daily
Number of subjects: 274
Study 17042147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 14572578 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day)
Number of subjects: 32
Study 14572578 — intervention group
Group type: COMPARATOR
Intervention: Etidronate (400 mg/day)
Number of subjects: 32
Study 14572578 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 32
Study 14572578 — intervention group
Group type: COMPARATOR
Intervention: Etidronate
Number of subjects: 32
Study 14572578 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 32
Study 10933081 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 20
Study 10933081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9412432 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise on a treadmill
Number of subjects: 8
Study 9412432 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting measurements
Number of subjects: 8
Study 9412432 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate measurements
Number of subjects: 8
Study 9412432 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate during exercise
Number of subjects: 8
Study 9412432 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent on treadmill
Number of subjects: 8
Study 8412069 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA)
Number of subjects: 12
Study 8412069 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 12
Study 2951985 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 micrograms/day of ICI 118,630
Number of subjects: 33
Study 2951985 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 micrograms/day of ICI 118,630
Number of subjects: 33
Study 2951985 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms/day of ICI 118,630
Number of subjects: 33
Study 29091519 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized compression orthosis
Number of subjects: 24
Study 29091519 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 24
Study 28468229 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 0
Study 28468229 — intervention group
Group type: COMPARATOR
Intervention: Saline merocel pack (Control)
Number of subjects: 0
Study 24699556 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncoagulating P4 protein blend
Number of subjects: 21
Study 24699556 — intervention group
Group type: COMPARATOR
Intervention: Coagulating casein-dominant protein blends
Number of subjects: 21
Study 23756263 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion to raise haemoglobin to at least 10.0 g/dL
Number of subjects: 200
Study 23756263 — intervention group
Group type: COMPARATOR
Intervention: No transfusion unless definite symptoms of anaemia became apparent
Number of subjects: 200
Study 21392929 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computerized education module
Number of subjects: 686
Study 19875386 — intervention group
Group type: EXPERIMENTAL
Intervention: Gp IIb-IIIa inhibitors
Number of subjects: 10085
Study 16798772 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 2 mg h(‐1) (group R, n=22)
Number of subjects: 47
Study 16798772 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1 mg h(‐1) with morphine 8 microg h(‐1) (group RM, n=22)
Number of subjects: 47
Study 16798772 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg ml(‐1) for continuous spinal anaesthesia
Number of subjects: 47
Study 12783034 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (1200 mg x d-1)
Number of subjects: 24
Study 12783034 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (4000 mg x d-1)
Number of subjects: 24
Study 12783034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10839900 — intervention group
Group type: EXPERIMENTAL
Intervention: CIO (Continuous Insufflation of Oxygen) at a flow rate of 15 l/min
Number of subjects: 95
Study 10839900 — intervention group
Group type: COMPARATOR
Intervention: IPPV (Intermittent Positive Pressure Ventilation)
Number of subjects: 95
Study 9126126 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical consultation (Control)
Number of subjects: 20
Study 9126126 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbalization of risks and benefits (Experimental)
Number of subjects: 20
Study 8267430 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde blood cardioplegia combined with anterograde blood cardioplegia and warm reperfusion (group 2)
Number of subjects: 41
Study 8267430 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia (group 1)
Number of subjects: 41
Study 3544663 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum extraction
Number of subjects: 0
Study 3544663 — intervention group
Group type: COMPARATOR
Intervention: Forceps delivery
Number of subjects: 0
Study 29128417 — intervention group
Group type: EXPERIMENTAL
Intervention: SitLess
Number of subjects: 59
Study 29128417 — intervention group
Group type: EXPERIMENTAL
Intervention: ExMore
Number of subjects: 59
Study 26847832 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Hexose Correlated Compound (AHCC) 6.0 g for 2 months
Number of subjects: 75
Study 26847832 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Hexose Correlated Compound (AHCC)
Number of subjects: 75
Study 24596458 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Number of subjects: 328
Study 24596458 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 328
Study 24596458 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional impairment
Number of subjects: 328
Study 24596458 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous falls
Number of subjects: 328
Study 24596458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 328
Study 22354671 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with 15 ml 0.25% bupivacaine (group T, n=25)
Number of subjects: 50
Study 22354671 — intervention group
Group type: COMPARATOR
Intervention: No blockade (group C, n=25)
Number of subjects: 50
Study 22354671 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block (group T)
Number of subjects: 50
Study 22354671 — intervention group
Group type: COMPARATOR
Intervention: No blockade (group C)
Number of subjects: 50
Study 20113315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardi04-300 ml
Number of subjects: 94
Study 20113315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardi04-150 ml
Number of subjects: 94
Study 20113315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 17030155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 1978
Study 17030155 — intervention group
Group type: COMPARATOR
Intervention: Placebo controlled blood pressure lowering (ACE inhibitor-diuretic combination: perindopril-indapamide)
Number of subjects: 1978
Study 15853986 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with 3 or 5 MU IFN-alpha-2b thrice weekly and oral ribavirin (800-1200 mg/day) for 24 weeks
Number of subjects: 36
Study 15853986 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU IFN-alpha-2b
Number of subjects: 36
Study 15853986 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU IFN-alpha-2b
Number of subjects: 36
Study 15853986 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with IFN-alpha and ribavirin
Number of subjects: 36
Study 15853986 — intervention group
Group type: COMPARATOR
Intervention: HCV infection alone (control group)
Number of subjects: 36
Study 12030663 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined warfarin and aspirin, low doses
Number of subjects: 0
Study 12030663 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin alone, low doses
Number of subjects: 0
Study 12030663 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone, low doses
Number of subjects: 0
Study 12030663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10220795 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary biliary cirrhosis (PBC)
Number of subjects: 26